DiaCarta
Latest round
- Series B
Last raised
- Nov 2017
Total raised
- $53M
Investors
- 3
About DiaCarta
Established in 2016 and based in Nanjing, China, DiaCarta China operates as a molecular diagnostic technology developer that mainly provides molecular diagnostic services. It has branches and third-party inspection center qualifications in Shanghai, Tianjin, Taizhou and Hangzhou, and we also have branches in the United States. The company mainly provides molecular diagnostic services. It has four technology platforms, which are XNA®, isobDNA™, DigiPlex™, and high-throughput sequencing experimental platform. Products and services include ColoScape® for early screening of colorectal cancer, genetic testing for chemotherapy drugs, RadTox™ for radiotherapy monitoring, and 21-gene testing for breast cancer. The company generates revenue by providing molecular diagnostic services such as ColoScape® for early screening of colorectal cancer and genetic testing for chemotherapy drugs.
Who invested in DiaCarta
3 investors across 2 rounds
See all investors in DiaCarta
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about DiaCarta
Who invested in DiaCarta?
DiaCarta has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DiaCarta raised?
DiaCarta has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did DiaCarta last raise money?
DiaCarta's most recent round on record is a Series B, in Nov 2017.
What does DiaCarta do?
Established in 2016 and based in Nanjing, China, DiaCarta China operates as a molecular diagnostic technology developer that mainly provides molecular diagnostic services.
Where is DiaCarta headquartered?
DiaCarta is headquartered in Nanjing, China.
Which VCs invest in companies like DiaCarta?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at DiaCarta's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like DiaCarta? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.